Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2011

View Archived Issues

iBioLaunch platform expresses protein to be studied as vaccine against hookworm disease

NicOx's NCX-226 reduces symptoms of inflammation in murine model of lung fibrosis

Olanzapine oral and LAI formulations show similar effectiveness in schizophrenia

R1-1084 and R1-770 well tolerated by patients with metastatic renal cell carcinoma

RLY-5016 dose titration avoids hypokalemia in patients with heart failure and kidney disease

Intedanib has beneficial effects in TOMORROW trial in idiopathic pulmonary fibrosis

Scientists at GSK design new P2X7 receptor antagonists

Novel cyclic dipeptides for neurodegenerative diseases presented

New diacylglycerol O-acyltransferase 1 inhibitors patented

GSK claims new inhibitors of serine/threonine-protein kinase TNNI3K

Novel bromodomain-containing protein inhibitors disclosed

InterMune reports new NS5B inhibitors for hepatitis C

Nationwide Children's Hospital receives NIH grant to advance gene therapy for MPS IIIB

Initiation of phase I trial in pain triggers milestone payment to Evotec from Boehringer Ingelheim

First patient enrolled in high-dose cohort of phase II SHIGATEC trial

European Commission approves extended use of Carbaglu for organic acidemias

Dyax and Defiante Farmaceutica expand agreement for ecallantide in HAE

Cleveland BioLabs and BARDA advance negotiations relating to development of CBLB-502

Affymax and Takeda submit NDA for peginesatide in anemia associated with chronic renal failure

GenKyoTex raises funds to develop NADPH oxidase inhibitors

Nuron Biotech to use PolyTherics' TheraPEG technology for long-acting MS therapy

BioSante completes enrollment in phase III safety study of LibiGel

Capstone Therapeutics and BiolineRx sign agreement for development of Chrysalin in AMI

Diamyd Medical stops follow-up in European phase III study of Diamyd in diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...